Evidence map›Paper›PMID 29255527›Full record

ArticleJournal of rural medicine : JRM2017

A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma.

Taku Naiki, Keitaro Iida, Noriyasu Kawai, Toshiki Etani, Ryosuke Ando, Takashi Nagai, Yutaro Tanaka, Shuzo Hamamoto, Takashi Hamakawa, Hidetoshi Akita and 2 more

Abstract read
In one paragraph

Article in Journal of rural medicine : JRM, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Taku NaikiDepartment of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Japan.
Keitaro IidaDepartment of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Japan.
Noriyasu KawaiDepartment of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Japan.
Toshiki EtaniDepartment of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Japan.
Ryosuke AndoDepartment of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Japan.
Takashi NagaiDepartment of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Japan.
Yutaro TanakaDepartment of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Japan.
Shuzo HamamotoDepartment of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Japan.
Takashi HamakawaDepartment of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Japan.
Hidetoshi AkitaDepartment of Urology, Anjo Kosei Hospital, Japan.
Yosuke SugiyamaDepartment of Pharmacy, Nagoya City University Hospital, Japan.
Takahiro YasuiDepartment of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

gemcitabine and paclitaxelmetastasissystemic chemotherapythird-lineurothelial carcinoma

Identifiers

PMID29255527
PMCPMC5721294

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.